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The effect of valsartan, an angiotensin II-type I receptor blocker, on the mitochondrial function, was studied using an ex vivo animal
model (hearts from Wistar rats), perfused in a Langendorff system and then submitted to global acute ischemia. Parameters evaluated
were: membrane electrical potential (DW, using a tetraphenylphosphonium-TPP+-electrode), oxygen consumption by the respiratory chain
(Clark-type O2 electrode), phosphorylation lag phase (time necessary to phosphorylate a fixed amount of ADP) and ATP/ADP ratio
(adenine nucleotides quantified by high-pressure liquid chromatography—HPLC). Valsartan acts preferentially in the phosphorylation,
increasing ATP/ADP ratios (succinate: 1.6T0.4 versus 0.5T0.1—P <0.05; ascorbate/N,N,N V,N V-tetramethyl-P-phenylenodiamine-TMPD:
1.1T0.2 versus 0.4T0.1—p <0.05 versus ischemia in the absence of valsartan) and decreasing lag phase (glutamate/malate: 50.0T9.6 s
versus 127.2T19.03 s–84.6T16.2% versus 215.3T32.2%; P=0.01; succinate: 111.8T33.1 s versus 275.73T45.99 s–168.2T49.8% versus
414.9T69.2%; P=0.02 or ascorbate/TMPD: 11.0T3.9 s versus 62.4T11.63 s–34.9T12.4% versus 198.1T36.9%; P=0.001 versus
ischemia in the absence of valsartan). This enables a higher energy production in hearts submitted to acute ischemia, for which having
energy becomes critical to preserve mitochondrial function. These mechanisms allow us to better understand valsartan cytoprotection in
ischemic cardiomyopathy.
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Mitochondria are the main cellular energy production
centers. Their importance regarding cell metabolism is pro-
portional to cellular energy requirements. Cardiomyocytes,
the paradigm of high energy consuming cells, have their
survival tightly connected to a normal mitochondrial func-
tion. In turn, mitochondria are commonly a major target for
cardiomyocyte stress factors, like ischemia.0014-2999/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejphar.2005.06.013
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E-mail address: lgoncalv@ci.uc.pt (L.M. Gonc¸alves).Valsartan is a tetrazol–byphenil–valinic derivative of lo-
sartan, structurally characterized by the presence of a sole
heterocyclic structure (Bauer and Reams, 1995). Function-
ally, valsartan is a highly selective non-competitive angio-
tensin II-type I (AT1) receptor antagonist (30,000 times higher
affinity for AT1 than for angiotensin II-type 2 receptors—
AT2) (Criscione et al., 1993). Valsartan has showed to be
effective in decreasing blood pressure values (inmonotherapy
or in combination with other anti-hypertensive drugs) and
treating heart failure (on top of optimal therapy, including
angiotensin converting enzyme inhibitors) (Kim et al., 2001;
Multani et al., 2001a,b; Palatini et al., 2001).
Studies performed in animal models of acute myocar-
dial infarction showed that valsartan decreases both
reactive oxygen species production (Kuno et al., 2002)ogy 518 (2005) 158 – 164
P. Monteiro et al. / European Journal of Pharmacology 518 (2005) 158–164 159and ventricular remodeling (Yu et al., 2001). In order to
assess if the post-acute myocardial infarction positive
effects also occur in humans, a large-scale randomized
clinical trial was recently conducted (Pfeffer et al.,
2003a,b) and its results clearly support the reported animal
data. In animal models of heart failure, valsartan showed a
positive effect regarding remodeling (even in animals on
angiotensin converting enzyme inhibitors) (Richer et al.,
2001), therefore improving left ventricular function and
survival (Kim et al., 2001). These effects can be
bradykinin (valsartan increases bradykinin levels) (Multani
et al., 2001a,b) and nitric oxide-mediated (Liu et al., 2002)
and were partially confirmed in heart failure patients (Cohn
and Tognoni, 2001). In animal models of hypertension,
valsartan was shown to have an anti-apoptotic effect (der
Sarkissian et al., 2003). Although many cellular actions of
valsartan are well established, its impact on mitochondrial
function during acute myocardial ischemia remains largely
unknown.
Therefore, our aim was to assess if valsartan could have
mitochondria as intracellular targets against damage caused
by global ischemia, using an ex vivo model of perfusion with
a Langendorff system.2. Material and methods
This investigation conformed with the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes
of Health—NIH publication No. 85-23, revised 1996—(National
Research Council, 1996) and it was approved by the Ethics
Committee of the Centre for Neuroscience and Cell Biology of
Coimbra, where the experimental work took place. All compounds
were of the purest quality available and were ordered from Sigma
Chemical Co. (St. Louis, MO) or Merck (Darmstadt, Germany),
except for valsartan that was obtained from Novartis (Basel,
Switzerland).
2.1. Experimental groups
Thirty Wistar rats were randomly assigned into three experimen-
tal groups: control (n =10), ischemia (n =10) and ischemia+valsar-
tan 1 nM (n =10).
2.2. Assembly of the ex vivo perfusion system
Wistar rats, weighing around 300 g, were killed by CO2 inha-
lation. Each heart was rapidly excised and mounted in a Langen-
dorff perfusion apparatus (model UP-100 from Hugo Sachs Elek-
tronik,Germany) and then perfused at a constant flow (25 mL/min)
with a Krebs modified solution (NaCl 118 mM, KCl 4.7 mM,
KH2PO4 1.2 mM, NaHCO3 25 mM,MgSO4 1.2 mM, Na2EDTA 0.5
mM, glucose 10 mM and CaCl2 3 mM; pH 7.4) and gassed with
carbogen (95%O2–5%CO2). Temperature was continuously moni-
tored and maintained at 37 -C (via a thermostatic bath) throughout
the perfusion period (180min for the control group and 60min for the
remaining groups); pH was also continuously monitored with a pH
electrode and kept stable at 7.35–7.45 during this period. Valsartan
at 1 nM was added to the Krebs modified solution in the respectiveexperimental groups (after pilot experiments, this dose was chosen
because it was the lowest dosewith positive impact onmitochondrial
function). Left ventricular pressure and heart rate were recorded
at regular intervals. After the initial perfusion, all rat hearts, with
the exception of the control group, were submitted to 120 min of
ischemia at 37 -C in a solution identical to that of the perfusion
period, but without glucose and carbogen (at the beginning of the
ischemic period, the perfusion flow—with carbogen—was stopped
and the hearts were submitted to no-flow ischemia; in order to
maintain temperature—37 -C—, they were immersed in Krebs
modified solution—without glucose and carbogen—that was
previously gassed with nitrogen). The time of ischemia was chosen
after performing pilot experiments, designed to determine the time
of ischemia (without reperfusion) needed to significantly impair
cardiac mitochondrial function.
2.3. Preparation of the biological material
2.3.1. Isolation of rat heart mitochondria
At the end of the perfusion and ischemia periods, the
mitochondrial fraction from each rat heart was prepared according
to the method described by Rickwood et al. (1987a). All the
parameters of mitochondrial function were assessed in the isolated
mitochondrial fraction.
2.4. Laboratorial methods used
2.4.1. Determination of protein concentration
The protein concentration of the mitochondrial fraction was
determined using the biuret colorimetric method (Gornall et al.,
1949).
2.4.2. Determination of the mitochondrial membrane potential
Membrane electrical potential (DW) was determined through the
permanent recording of the distribution of the lipophilic cation tetra-
phenylphosphonium (TPP+) across the inner mitochondrial mem-
brane. This was done with an electrode sensitive to TPP+ prepared in
our laboratory, according to the principles established by Kamo et al.
(1979). Reactions took place at a constant temperature of 25 -C, in
an open and thermostable reaction chamber, using 1 ml of reaction
solution (sucrose 130 mM, KCl 50 mM, MgCl2 5 mM, KH2PO4 5
mM and (N-[2-hydroxyethyl] piperazine-NV-[2-ethanosulphonic])
acid (HEPES) 5 mM, pH 7.2), supplemented with 3 AM TPP+ and
the mitochondrial suspension (volume corresponding to 2 mg of
protein, as determined by the biuret method). The determination of
mitochondrial DW was performed using the method described by
Muratsugu et al. (1977) and Kamo et al. (1979). The matrix volume
was assumed to be 1.1 Al/mg of protein.
2.4.3. Evaluation of mitochondrial respiratory activity
All the assays were performed at 25 -C, in a closed reaction
chamber, with stable temperature and 1 ml capacity.
Oxygen consumption was evaluated polarographically with an
O2 electrode (Yellow Springs Instruments, Co.), Clark type,
connected to a Kipp & Zonen recorder, through a command unit
manufactured at our laboratory. Electrode calibration was done
according to the protocol described by Rickwood et al. (1987b).
Reactions were initiated by adding the mitochondrial suspension
to the reaction solution (as previously described). The later addition
of the respiratory substrate [glutamate 10 mM+malate 5 mM,
succinate 5 mM or ascorbate 5 mM+N,N,N V,N V-tetramethyl-P-
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consumption by the mitochondrial fraction. Respiratory state 3
(characterized by a higher and faster O2 consumption) was then
induced by the addition of adenosine diphosphate (ADP) 250 nmol
(62.5 nmol when using ascorbate/TMPD). After all ADP was con-
sumed, the reaction returned to a slower velocity, respiratory state
4. Respiratory control ratio was evaluated as the quotient between
state 3 and state 4.
2.4.4. Evaluation of the ATP/ADP ratio
The protocol for extraction of the adenine nucleotides (ATP,
ADP and AMP) was as follows: at the end of one phosphorylation
cycle induced by the addition of ADP, 250 Al of the final
respiratory medium was collected (corresponding to 0.5 mg of
mitochondrial protein) and added to 250 Al of HClO4 0.6 M (with
25 mM of EGTA). Five minutes later, the mixture was agitated in a
vortex (to obtain a protein-free sample) and centrifuged for 2 min at
10,000g in an Eppendorf centrifuge (at 0 -C). The pellet was then
removed and the supernatant was neutralised with KOH 3 M+Tris
1.5 M and then centrifuged at 10,000g for another 2 min. All pro-
cedures were conducted at low temperature (0–4 -C). The adenine
nucleotides were separated by high-pressure liquid chromatography
(HPLC), reverse phase (Stocchi et al., 1985), in a Beckman Gold
chromatograph, with a model 126 pump and a variable UV detector
(model 166), controlled by a computer. The detection wavelength
was 254 nm, using a Licrosphere 100 RP-18 column (5 mm) made
by Merck (Darmstad, Germany). The protocol used consisted of
isocratic elution with potassium phosphate buffer (100 mM; pH 6.5)
and methanol 1%. The flow rate was 1.25 ml/min for 5 min (to
achieve nucleotide separation) and the detection limit for each com-
pound was 3 to 5 pmol. The ATP/ADP ratio was then determined.
2.5. Statistical analysis
Results are presented as meansTS.E.M. (raw data or expressed
as percentage of control), for the number of results indicated.Non-ischemic Ischemic 90 min Ischemic
ADP 
ADP






Fig. 1. Typical sample for the mitochondrial membrane potentialResults were analyzed using the one-way ANOVA test. The level
of significance used was P <0.05.3. Results
As it was previously demonstrated by several authors (Corbucci,
2000; Ylitalo et al., 2001; Marin-Garcia and Goldenthal, 2002), our
results clearly show that oxidative phosphorylation is very sensitive
to ischemia, which dramatically affects mitochondrial respiratory
chain (Fig. 1), as it can be shown by the decrease in the respiratory
control ratio [that is, the ratio between the oxygen consumption
during active phosphorylation (state 3) and after active phosphor-
ylation (state 4)], when compared to the value obtained in
mitochondria from the control group (2.71 T0.42 versus
1.51T0.13; P=0.0002). Valsartan (1 nM) did not significantly
affected this parameter when using glutamate/malate as energy
substrate (respiratory control ratio—1.56T0.1 versus 1.51T0.13;
P=not significant), although there was a significant increase in
oxygen consumption by mitochondria from valsartan-treated
hearts, both in state 3 (115.5T17.2 versus 73.6T7.0 natm
oxygen/min/mg protein; P <0.05) and state 4 (73.4T9.1 versus
49.8T6.0 natm oxygen/min/mg protein; P <0.05) of mitochon-
drial respiration (Table 1).
When testing glutamate/malate as energy substrate, a decrease
in mitochondrial membrane electrical potential (DW), determined
by a TPP+-sensitive electrode, was observed in mitochondria
from the hearts of the ischemic group, when compared to those of
the control group (209.1 T1.4 versus 186.7 T3.4 mV;
P=0.000001). A similar result was found when using succinate
(211.3T3.2 versus 187.2T4.7 mV; P <0.05) and ascorbate/TMPD
(209.1T2.5 versus 189.2T4.0 mV; P <0.05) as energy substrates.
Valsartan significantly improved DW, when glutamate/malate was
used as energy substrate (206.9T3.0 versus 186.7T3.4 mV;
P=0.01). Similar results were obtained when using succinate




and phosphorylation time for different periods of ischemia.
Table 1
Oxygen consumption in states 3 and 4 of mitochondrial respiration, using glutamate/malate as energy substrate
Parameters/groups Control Ischemic Valsartan
Oxygen consumption—state 3 (natm oxygen/min/mg protein) 97.7T10.4 73.6T7.0a 115.5T17.2b
Oxygen consumption—state 4 (natm oxygen/min/mg protein) 36.9T2.5 49.8T6.0a 73.4T9.1b
Respiratory control ratio 2.71T0.42 1.51T0.13a 1.56T0.1
ADP/oxygen 2.79T0.3 1.45T0.22a 1.83T0.24
aP <0.05 versus the control group and bP <0.05 versus the ischemic group.
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189.2T4.0 mV), although without reaching statistical significance
(P=0.17)—Table 2.
Another parameter evaluated was the time needed to phosphor-
ylate a fixed amount of ADP (phosphorylation time). The shorter it
is, the faster a phosphorylation cycle is completed. Independently
of the energy substrate used, we have observed a significant
increase in the phosphorylation time when using mitochondria
from the hearts of the ischemic group, compared with mitochondria
from the control group (glutamate/malate: 59.1T6.8 versus
127.2 T19.0 s—P = 0.001; succinate: 66.5 T6.4 versus
275.7T46.0 s—P=0.0001; ascorbate/TMPD: 31.5T2.1 versus
62.4T11.6 s—P=0.001). When compared to the ischemic group,
mitochondria from the hearts treated with valsartan were able to
significantly decrease lag phase and that was consistent regardless
of the energy substrate used (glutamate/malate: 50.0T9.6 versus
127.2T19.0 s—P=0.01; succinate: 111.8T33.1 versus 275.7T46.0
s—P=0.02; ascorbate/TMPD: 11.0T3.9 versus 62.4T11.6 s—
P=0.001)—Table 3.
As previously described, the ATP/ADP ratio was also assessed,
for each of the energy substrates used (adenine nucleotides—AMP,
ADP and ATP were measured after a phosphorylation cycle, using
HPLC). Once again, the mitochondria from the ischemic group
were shown to have inferior ATP/ADP ratio when compared to
mitochondria from the control group, regardless of the substrate
used (glutamate/malate: 27.5T8.9 versus 10.9T1.3—P <0.05;
succinate: 4.4T0.7 versus 0.5T0.1—P <0.05; ascorbate/TMPD:
1.3T0.5 versus 0.4T0.1—P <0.05)—Table 4. When compared toTable 2
Comparison between maximal electrical potential (DW) in the ischemic and
valsartan-treated hearts, after the addition of the energy substrate to the
reaction medium containing rat heart mitochondria













A – glutamate/malate; B – succinate; C – ascorbate/TMPD. Values are
presented in mV.
aP <0.05 versus the control group and bP <0.05 versus the ischemic group.the ischemic group, mitochondria from valsartan-treated hearts
showed a significantly higher ATP/ADP ratio, when succinate and
ascorbate/TMPD were used as energy substrates (glutamate/
malate: 10.0T8.6 versus 10.9T1.3—P=not significant; succinate:
1.6T0.4 versus 0.5T0.1—P <0.05; ascorbate/TMPD: 1.1T0.2
versus 0.4T0.1—P <0.05). When using glutamate/malate, ratios
were similar in both experimental groups (10.0T8.6 versus
10.9T1.3; P=not significant)—Table 4.
4. Discussion
Valsartan, in the concentration used in this experimental
protocol (1 nM), revealed a beneficial effect, although un-
evenly distributed by the oxidative and phosphorylative sys-
tems. This statement is validated by a cautious analysis of
the results obtained: in parameters assessing the phosphory-
lative system, namely phosphorylation time and ATP/ADP
ratios, improvements were statistically significant (except
for ATP/ADP ratio when glutamate/malate was used),
resulting in an increase of DW, independently of the energy
substrate used. On the contrary, no improvement was seen
on respiratory control ratio values due to a balanced increase
in oxygen consumption in ADP-stimulated oxygen con-
sumption during the active phosphorylation (energy sub-
strate-dependent)—state 3— and during the phase after the
active phosphorylation—state 4.Table 3
Comparison of the phosphorylation time in the ischemic and valsartan-
treated hearts, after the addition of the energy substrate to the reaction
medium containing rat heart mitochondria













A – glutamate/malate; B – succinate; C – ascorbate/TMPD. Values are
presented in s.
aP <0.05 versus the control group and bP <0.05 versus the ischemic group.
Table 4
Levels of ADP, ATP and their ratio, for each experimental group (control,
ischemic and valsartan) and for each energy substrate used (glutamate/
malate, succinate and ascorbate/TMPD), after the conclusion of the
phosphorylation cycle
Parameters/groups ADP ATP ATP/ADP
ratio(nmol/mg protein) (nmol/mg protein)
Glutamate/malate
Control 2454T470 67510T20420 27.5T8.9
Ischemic 4855T1114 52930T6865 10.9T1.3a
Valsartan 8513T2343 85074T10336 10.0T8.6
Succinate
Control 14755T2987 64292T22358 4.4T0.7
Ischemic 74454T4832 38979T10166 0.5T0.1a
Valsartan 30653T8156 49694T12231 1.6T0.4b
Ascorbate/TMPD
Control 5234T792 6688T1930 1.3T0.5
Ischemic 8597T1175 3158T519 0.4T0.1a
Valsartan 5358T2372 6118T1862 1.1T0.2b
aP <0.05 versus the control group and bP <0.05 versus the ischemic group.
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other studies, which have already shown valsartan to
have a positive impact in the setting of acute ischemia
(post-acute myocardial infarction), by decreasing reactive
oxygen species production (Kuno et al., 2002). Our data
clearly show that, by also improving and accelerating
ATP production, valsartan has a positive effect on the
cellular and subcellular events that take place during
acute ischemia. A shorter lag phase is synonymous of
faster ADP phosphorylation; this represents a clear
advantage, as the ionic gradients can be more rapidly
restored once oxygen is added to the system and
mitochondria resume ATP pro-duction (that is, in turn,
also improved). Several authors, using animal models or
human patients, clearly showed that valsartan decreases
reactive oxygen species production (Ku-no et al., 2002)
and has anti-apoptotic effects (der Sarkissian et al., 2003).
Being ischemia an imbalance between energy supply and
demand and being the mitochondria the main site of
energy production within the cell, we hypothesized that
valsartan, by allowing a faster and higher ATP production
in the ischemic myocardium, can contribute to the
preservation of the mitochondrial function (as our data
regarding electrical potential show, being the preservation
of electrical potential energy-dependent and membrane
integrity-dependent). Being the mitochondria both a major
potential reactive oxygen species producer and reactive
oxygen species target, an im-proved mitochondrial function
is synonymous of lower re-active oxygen species production
(or else mitochondrial membrane integrity would be lost by
lipoperoxidation and/or by mitochondrial permeability tran-
sition induction, a phenomenon that is reactive oxygen
species-dependent) (Oliveira et al., 2003) and, therefore,
improved cell survival (because reactive oxygen species are a
major inducer of cell death, either by necrosis, if there is amassive decrease in energy production, or by apoptosis,
because mitochondrial permeability transition leads to
cytochrome c release from the mitochondria and caspase
cascade activation). The results of the recently published
VALIANT trial (Pfeffer et al., 2003a,b) provide the clinical
support to this hypothesis, by demonstrating the significant
impact of val-sartan on left ventricular function and long-term
patient survival.
Previously published papers (Multani et al., 2001a,b;
Liu et al., 2002) supported the idea that AT1-receptor
antagonists can act directly on the cardiomyocyte and that
both nitric oxide and bradykinin are important mediators
of this cardioprotection and can initiate signaling path-
ways that lead to improved cellular function and cell
survival. What our data showed was that mitochondria
play an important role in this cardioprotection because
valsartan can improve ATP availability, essential to
preserve left ventricular function (myocardium is highly
dependent on ATP produced within the mitochondria to
preserve its contractile function, especially during periods
of energy shortage, like prolonged ischemia). Regarding
remodeling, it is well known that angiotensin II is one of
its major determinants, due to increased collagen produc-
tion (and, therefore, cardiac fibrosis); apoptosis is also
important for remodeling and in some animal models
valsartan was shown to be anti-apoptotic (der Sarkissian
et al., 2003), although other forms of cell death besides
apoptosis can be prevalent in cardiac remodeling (Hein et
al., 2002); by preserving mitochondrial function and, thus,
energy production, during acute ischemia, we hypothesize
that valsartan-treated hearts will be less prone to
remodeling due to two complementary mechanisms:
improved ATP production and decreased angiotensin-
induced fibrosis.
Using a similar protocol, our research team already de-
monstrated a positive impact of both carvedilol (Monteiro
et al., 2003) and trimatazidine (Monteiro et al., 2004).
These studies clearly show that many anti-ischemic drugs act
on mitochondrial metabolism during cardiac ischemia, either
by accelerating and improving energy production (like
carvedilol and valsartan, two drugs that act on the two
neurohumural key factors regarding cardiac response to stress:
the sympathetic system and the renin–angiotensin–aldoster-
one system) or by improving the function of specific
components of the respiratory chain (like trimetazidine, an
anti-ischemic agent without significant haemodynamic
effect). Based on these results, we can speculate that behind
the good clinical results of many anti-ischemic drugs is an
improvement of the cardiac mitochondrial function after an
ischemic insult.
In conclusion, results reported in this manuscript allow
us to unveil most of the mechanisms for valsartan
cardioprotective effects in coronary artery disease patients,
mainly in an acute ischemia setting. By promoting a faster
and better activity of the mitochondrial phosphorylative
system during acute ischemia, valsartan may help to
P. Monteiro et al. / European Journal of Pharmacology 518 (2005) 158–164 163overcome one of the most deleterious effects of ischemia
(decreased ATP availability), resulting in a positive impact
on cardiac mitochondrial function. Therefore, valsartan, by
ensuring an improved energy production in ischemic
cardiomyocytes, equally allows the improvement of some
energy-dependent mitochondrial function parameters, like
the maintenance of an adequate electrical potential. Global-
ly, valsartan has a positive effect on mitochondrial function
and, therefore, on ischemic cardiomyocytes metabolism.
These data can help us to better explain valsartan
cytoprotective effect in myocardial ischemia, thus opening
new perspectives in the treatment of ischemic heart disease,
a leading cause of morbidity and mortality in Western
societies.Acknowledgements
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